EX-99.1 2 ea022025701ex99-1_mdxhealth.htm FINANCIAL RESULTS FOR THE THIRD QUARTER AND THE THREE- AND NINE-MONTH PERIODS ENDED SEPTEMBER 30, 2024

Exhibit 99.1

 

 

 

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

 

   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
Thousands of $ (except per share data)  2024   2023   2024   2023 
                 
Revenues   23,317    19,350    65,310    50,795 
Cost of sales (exclusive of amortization of intangible assets)   (9,042)   (6,797)   (25,686)   (19,537)
Gross Profit   14,275    12,553    39,624    31,258 
Research and development expenses   (2,697)   (1,557)   (7,764)   (4,547)
Selling and marketing expenses   (10,619)   (9,060)   (31,280)   (27,431)
General and administrative expenses   (5,735)   (5,381)   (16,936)   (16,280)
Amortization of intangible assets   (1,327)   (1,128)   (3,575)   (3,367)
Other operating income (expense), net   11    12    (183)   (654)
Operating loss   (6,092)   (4,561)   (20,114)   (21,021)
Financial income   197    564    1,772    1,570 
Financial expense   (4,960)   (6,048)   (12,552)   (12,929)
Loss before income tax   (10,855)   (10,045)   (30,894)   (32,380)
Income tax   (334)   -    (334)   - 
Loss for the period   (11,189)   (10,045)   (31,228)   (32,380)
                     
Loss per share attributable to parent                    
Basic and diluted   (0.40)   (0.37)   (1.14)   (1.27)

 

 

 

 

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

 

Thousands of $ 

as of

September 30,
2024

  

as of

December 31,
2023

 
ASSETS        
Goodwill   35,926    35,926 
Intangible assets   41,924    44,337 
Property, plant and equipment   4,672    4,956 
Right-of-use assets   3,870    4,989 
Financial assets   822    763 
Non-current assets   87,214    90,971 
Inventories   4,384    2,779 
Trade receivables   14,993    11,088 
Prepaid expenses and other current assets   1,545    1,914 
Cash and cash equivalents   49,272    22,380 
Current assets   70,194    38,161 
Total assets   157,408    129,132 
EQUITY          
Share capital   213,931    173,931 
Issuance premium   149,859    153,177 
Accumulated deficit   (362,674)   (331,446)
Share-based compensation   16,458    12,139 
Translation reserve   (580)   (593)
Total equity   16,994    7,208 
           
LIABILITIES          
Loans and borrowings   50,873    35,564 
Lease liabilities   2,537    3,578 
Other non-current financial liabilities   41,463    63,259 
Non-current liabilities   94,873    102,401 
Loans and borrowings   485    643 
Lease liabilities   1,440    1,480 
Trade payables   10,385    8,811 
Other current liabilities   7,331    5,694 
Other current financial liabilities   25,900    2,895 
Current liabilities   45,541    19,523 
Total liabilities   140,414    121,924 
Total equity and liabilities   157,408    129,132 

 

2

 

 

CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS

 

   Nine Months Ended
September 30,
 
Thousands of $  2024   2023 
CASH FLOWS FROM OPERATING ACTIVITIES        
Operating loss   (20,114)   (21,021)
Depreciation   2,271    1,910 
Amortization of intangible assets   3,575    3,367 
Share-based compensation   1,059    457 
Other non-cash transactions   (85)   276 
Cash used in operations before working capital changes   (13,294)   (15,011)
           
Changes in operating assets and liabilities          
Increase (-) in inventories   (1,605)   (541)
Increase (-) / decrease (+) in receivables   (3,536)   1,278 
Increase (+) in payables   3,023    151 
Net cash outflow from operating activities   (15,412)   (14,123)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property, plant and equipment   (996)   (2,399)
Acquisition and generation of intangible assets   (971)   (1,612)
Interest received   560    756 
Net cash outflow from investing activities   (1,407)   (3,255)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from issuance of shares, net of transaction costs   37,206    39,599 
Proceeds from loan obligation   53,051    - 
Repayment of loan obligation, loan modification, and debt extinguishment costs   (39,929)   (1,239)
Payment of lease liability   (1,409)   (1,121)
Payment of interest   (4,899)   (2,666)
Other financial expense   (306)   - 
Net cash inflow from financing activities   43,714    34,573 
           
Net increase in cash and cash equivalents   26,895    17,195 
           
Cash and cash equivalents at beginning of the period   22,380    15,503 
Effect of exchange rates   (3)   16 
Cash and cash equivalents at end of the period   49,272    32,714 

 

 

3